Compare Garmin Ltd. (GRMN) vs Johnson & Johnson (JNJ) Price & Performance

Garmin (GRMN) trades at $313.16, up 0.73% on the day and near its all-time high, with a bullish technical trend and strong support at $309. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.81 beating estimates of $2.30, and raised full-year guidance. Revenue growth accelerated to 11% in Q2 2026, driven by strong performance in the fitness segment, while net income margin improved to 24.47%.

The outlook remains positive given robust fundamentals and raised guidance, but risks include rich valuation multiples, potential growth deceleration, and insider selling. Analyst consensus is cautious with a hold-heavy rating, though the average price target of $318.67 suggests modest upside from current levels.

Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.

The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.